 MILAN, Italy and NEW YORK, Oct. 05, 2022 GLOBE NEWSWIRE -- Genenta Science NASDAQ: GNTA, a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming scientific and investor conferences. 